论文部分内容阅读
目的通过观察高效抗反转录病毒治疗(Highly active antiretroviral therapy,HAART)对心血管疾病(Cardiovascular disease,CVD)标志物脂联素(Adiponectin,APN)和超敏C反应蛋白(High-sensitivity C-reativeprotein,hs-CRP)的影响,判断与艾滋病病毒(Human immuno deficiency virus,HIV)感染、治疗相关的CVD发生、发展状况,为HIV感染者CVD的防治提供依据。方法对唐都医院127例HIV感染者和63名健康志愿者,采用酶联免疫吸附试验(Enzyme-linked immunosorbent assay,ELISA)检测APN和hs-CRP浓度,通过横向和纵向研究,观察APN和hs-CRP的变化。结果治疗组APN浓度为(3.35±3.21)μg/mL,明显低于未治疗组(6.34±6.93)μg/mL和对照组(5.34±5.44)μg/mL。hs-CRP检测结果三组之间没有差异。对治疗组36例患者进行随访,发现APN在24周前升高,在24周后逐渐降低,但是hs-CRP在随访中没有明显变化。结论在HAART中的HIV感染者,APN浓度先升后降,而hs-CRP并没有明显变化,动态监测这些指标有利于HIV感染者CVD的早期预防。
Objective To investigate the effects of highly active antiretroviral therapy (HAART) on cardiovascular disease markers such as Adiponectin (APN) and High-sensitivity C- reativeprotein and hs-CRP, and to determine the occurrence and development of CVD associated with HIV infection and treatment, so as to provide basis for the prevention and treatment of CVD in HIV-infected patients. Methods The levels of APN and hs-CRP in 127 HIV-infected and 63 healthy volunteers in Tangdu Hospital were detected by Enzyme-linked immunosorbent assay (ELISA). The levels of APN and hs-CRP -CRP changes. Results The APN concentration in the treatment group was (3.35 ± 3.21) μg / mL, which was significantly lower than that of the untreated group (6.34 ± 6.93) μg / mL and the control group (5.34 ± 5.44) μg / mL. hs-CRP test results no difference between the three groups. Follow-up of 36 patients in the treatment group showed that APN increased 24 weeks before, and gradually decreased after 24 weeks, but hs-CRP did not change significantly at follow-up. Conclusions In HAART patients with HIV infection, APN levels first and then decrease, while hs-CRP did not change significantly. The dynamic monitoring of these indicators is beneficial to the early prevention of CVD in HIV-infected patients.